ArticleCancer medicine2023
KLRF1, a novel marker of CD56
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Natural killer cell-based therapy for hepatocellular carcinoma (HCC): A literature review.Medical oncology (Northwood, London, England) · 2026Review
- Aligned cross-modal integration and regulatory heterogeneity characterization of single-cell multiomic data with deep contrastive learning.Genome medicine · 2026Article
- Uncovering the pivotal role of MYO6 in myocardial infarction: a multimodally validated diagnostic biomarker and immunotherapeutic target.Frontiers in immunology · 2026Article
- Identification of DNA Replication Stress-Related Genes as Prognostic Biomarkers for Bladder Cancer.Combinatorial chemistry & high throughput screening · 2026Article
- Integration of single-cell and bulk transcriptomics reveals the association of manganese metabolism-related genes with prognosis and immune infiltration in lung adenocarcinoma.Clinical & translational immunology · 2026Article
- Identification and single-cell analysis of prognostic genes related to mitochondrial and neutrophil extracellular traps in bladder cancer.Scientific reports · 2025Article
- Identification of ETV4 as a prognostic biomarker and correlates with immune cell infiltration in head and neck squamous cell carcinoma.Scientific reports · 2025Article
- Causal inference study of plasma proteins and blood metabolites mediating the effect of obesity-related indicators on osteoporosis.Frontiers in endocrinology · 2025Article
- Bioinformatic Analysis and Experimental Validation of HMGA2-AS1 as a Prognostic Biomarker Associated with Immune Infiltration in Gastric Cancer.Recent patents on anti-cancer drug discovery · 2025Article
- Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune Therapies.Cancer immunology research · 2024Review
- Diagnostic potential of genomic blood biomarkers of pulmonary fibrosis in a prospective cohort.PloS one · 2024Article
- KLRF1, a novel marker of CD56Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundBladder tumor-infiltrating CD56
methodsCD56
resultsIntratumoral CD56
conclusionsKLRF1 is a promising prognostic marker in bladder cancer and may guide treatment decisions upon validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.